First-in-human aXess graft trial shows high patency and low reintervention rates


“Absolutely novel and exciting”—that is how Frans Moll (University Medical Center Utrecht, Utrecht, The Netherlands) has described the aXess haemodialysis vascular graft as he reviewed the findings from a first-in-human trial at the 2023 Charing Cross Symposium (25–27 April, London, UK). 

Unassisted primary patency was found to be 80% at six months, while assisted was 89%. Highlighting the low rate of reintervention, Moll looks forward to the longer-term results from the study and argues that the graft promises “a bright future for our dialysis patients”. 


Please enter your comment!
Please enter your name here